News
In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval …
19226 items found
R&D
Health Innovators - Steve Damon
The hypodermic needle was invented in 1844 by Francis Rynd and, while …
News
Third Arc's $165m for T cell engagers, plus other bio rounds
This week's round-up of new financings in the biotech world is headed …
Sales & Marketing
Creative review: The Cannes Lions trends that pharma needs to know about
Pharma creative needs to stand up and be counted. That’s the message …
News
AZ joins call for new UK PM to back Oxford-Cambridge hub
In a letter to the new UK Prime Minister Keir Starmer, leading …
R&D
5 strategies for biopharma to optimise patient recruitment in clinical trials
Patient recruitment remains a significant challenge for biopharma …
News
Pfizer's haemophilia B gene therapy gets EU green light
There will soon be two gene therapies available for patients with …
News
Shingles shot could be a simple way to delay dementia
Vaccination with GSK's recombinant shingles vaccine, Shingrix, could …
News
ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC
FDA reviewers were so frustrated by AstraZeneca's application for …
Patients
Sponsored
Patient engagement throughout the product lifecycle
One of the things that makes patient engagement for pharma companies …
News
Ipsen builds again, licensing Day One glioma drug
Ipsen has signed yet another portfolio-expanding deal – its fifth of …
R&D
Ageing Europe - It’s time we prioritised neurological conditions
Europeans are living longer than ever before – tangible proof of the …
News
In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Digital
Sponsored
PDURS explained: The FDA’s new framework for adding software...
The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to t
Market Access
Rare diseases: the urgent need for health equity and acceler...
Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
R&D
Sponsored
Rare Disease Diagnostics: Advancing Orphan Drug Development ...
This white paper is free and can be downloaded and read at your convenience
Patients
Sponsored
Patient engagement throughout the product lifecycle
One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list.
Digital
Sponsored
Digital health innovation: Applications across the patient j...
Digital health innovation (DHI) is a growing category of technologies that connect healthcare stakeholders and improve patient experiences and outcomes.
R&D
Partner Content
Novo Nordisk seeks to target heart disease with Cardior acqu...
Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their
R&D
Partner Content
6th Inflammasome Therapeutics Summit
In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
